In continuation of the Company''s submission dated 16th January 2025, this is to inform you that the Directors of the Company have at their meeting held on 13th May 2025 resolved to acquire ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries has approved acquiring 100% of Dubai-based Cibachem General Trading L.L.C. (300 shares of AED 1,000 each) at a revised consideration of Rs. 55 lakhs, more than double the earlier approved price of Rs. 25 lakhs from January 2025. Cibachem is a small UAE general trading company with turnover of around AED 4-5 lakhs in each of the last three years. The acquisition is purely a cash deal, not a related-party transaction, and needs only RBI automatic-route approval under overseas investment rules. The company says the goal is to grow its customer base in the Middle East region. Expected completion is by 30th September 2025.
The deal is small in size (Rs. 55 lakhs) relative to most pharma companies, so financial impact is limited. However, the sharp upward revision in price (from Rs. 25 lakhs to Rs. 55 lakhs) is worth noting — it may raise questions on valuation discipline. Strategically, it signals Sudarshan Pharma's intent to expand internationally into the UAE trading space.